These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 17053985)

  • 1. Mathematical assessment of properties of precursor-dependent indirect pharmacodynamic response models.
    Hazra A; Krzyzanski W; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2006 Dec; 33(6):683-717. PubMed ID: 17053985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena.
    Sharma A; Ebling WF; Jusko WJ
    J Pharm Sci; 1998 Dec; 87(12):1577-84. PubMed ID: 10189270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of four basic models of indirect pharmacodynamic responses.
    Sharma A; Jusko WJ
    J Pharmacokinet Biopharm; 1996 Dec; 24(6):611-35. PubMed ID: 9300353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated functions for four basic models of indirect pharmacodynamic response.
    Krzyzanski W; Jusko WJ
    J Pharm Sci; 1998 Jan; 87(1):67-72. PubMed ID: 9452970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mathematical formalism for the properties of four basic models of indirect pharmacodynamic responses.
    Krzyzanski W; Jusko WJ
    J Pharmacokinet Biopharm; 1997 Feb; 25(1):107-23. PubMed ID: 9353696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mathematical formalism and characteristics of four basic models of indirect pharmacodynamic responses for drug infusions.
    Krzyzanski W; Jusko WJ
    J Pharmacokinet Biopharm; 1998 Aug; 26(4):385-408. PubMed ID: 10214559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of drug interactions relevant to pharmacodynamic indirect response models.
    Earp J; Krzyzanski W; Chakraborty A; Zamacona MK; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2004 Oct; 31(5):345-80. PubMed ID: 15669772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methods of estimation of IC50 and SC50 parameters for indirect response models from single dose data.
    Wyska E; Mager DE; Krzyzanski W
    J Pharm Sci; 2003 Jul; 92(7):1438-54. PubMed ID: 12820148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A theory of drug tolerance and dependence II: the mathematical model.
    Peper A
    J Theor Biol; 2004 Aug; 229(4):491-500. PubMed ID: 15246786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent adaptation. A theory of drug tolerance, dependence and addiction.
    Peper A
    Pharmacopsychiatry; 2009 May; 42 Suppl 1():S129-43. PubMed ID: 19434551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-lasting rebound cue effects following single doses of nicotine and amphetamine: implications for understanding tolerance.
    Barrett RJ; Caul WF; Stadler JR; Smith RL
    Psychopharmacology (Berl); 2001 Oct; 157(4):349-57. PubMed ID: 11605093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of basic indirect pharmacodynamic response models with physiological limits.
    Yao Z; Krzyzanski W; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2006 Apr; 33(2):167-93. PubMed ID: 16547797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs.
    Gardner SN
    Cancer Res; 2000 Mar; 60(5):1417-25. PubMed ID: 10728708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
    Meibohm B; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choice of number of doses for maximum likelihood estimation of the ED50 for quantal dose-response data.
    Müller HG; Schmitt T
    Biometrics; 1990 Mar; 46(1):117-29. PubMed ID: 2350566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A theory of drug tolerance and dependence I: a conceptual analysis.
    Peper A
    J Theor Biol; 2004 Aug; 229(4):477-90. PubMed ID: 15246785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of baseline parameters in determining indirect pharmacodynamic responses.
    Sun YN; Jusko WJ
    J Pharm Sci; 1999 Oct; 88(10):987-90. PubMed ID: 10514344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.